For Immediate Release November 1, 2017
As part of the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud, the agency today issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these outcomes. Selling these unapproved products with unsubstantiated therapeutic claims is not only a violation of the Federal Food, Drug and Cosmetic Act, but also can put patients at risk as these products have not been proven to be safe or effective. The deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.
“I am not pro-cannabis; I think 90% is placebo.”
“LAST YEAR DEDI MEIRI, A CANNABIS RESEARCHER AT THE TECHNION, ISRAEL’S OLDEST UNIVERSITY, RECEIVED A “BEFORE AND AFTER” VIDEO OF AN AUTISTIC BOY.
The before showed the boy helmeted, hands tied behind his back, butting his head against a wall. The after showed him calmly sitting at a table, sketching. The difference: two drops of cannabis oil administered below the tongue. The video had been sent to Meiri by Abigail Dar, an Israeli champion for the use of cannabis in children with autism.
Early this year it was a different story. Over the course of a day, Meiri’s lab received a stream of phone calls from Dar: a few autistic children had gone berserk after receiving their two drops of oil.”
Alex White, EXCLUSIVE, Herald Sun October 28, 2017
MEDICINAL cannabis is no better than conventional drugs for treating children with severe epilepsy, according to a top Victorian doctor.
After months of treatment, none of the 29 Victorian children accessing $1 million worth of medicinal cannabis product, imported from Canada, has been seizure free.
Paediatric neurologist Professor Ingrid Scheffer told the Sunday Herald Sunmedicinal cannabis had been effective in some of the cases by reducing fits among some of the group.
However, the results had been similar to outcomes achieved on other pharmaceutical drugs and it was not the miracle solution families were hoping for.
Families hear the news kids who need cannabis to help with chronic illness will gain access. Picture: Jason Edwards
“Initially we all had a sense of hope but that didn’t last but that is the nature of these diseases,” Prof Scheffer said.
Some of the samples contained a petroleum derivative and household disinfectant. Graphic: Simon Rankin
EXCLUSIVE Christiane Barro
Seriously ill patients who are turning to medical cannabis for life-saving treatment are being sold fake, poisonous and intoxicating products manufactured in backyard laboratories across Australia.
The unlicensed suppliers are sending cannabis oil that contains dangerous chemicals that could lead to cancer, and then charging people $6000 for up to three months’ supply.
The unregulated products have put patients’ lives in serious danger with several reports of abuse and the leak of private patients’ details. During a six-month investigation, The New Daily was sent 14 different samples of cannabis extract from concerned customers of three different illegal suppliers.
A top Australian research facility, which did not want to be named, independently tested these products for the amount of cannabidiol (CBD) and tetrahydrocannabinol (THC), the two most active ingredients in the cannabis plant.
When that data was analysed by Safe Work Laboratories, 13 products were found to have no medicinal value, contained hazardous solvents or were heavily intoxicating.
Alicia Wallace - The Denver Post
October 6, 2017
Cannabidiol is a non-psychoactive cannabis compound touted for its medicinal promise, but marijuana and hemp-derived extracts rich in CBD and low in intoxicating THC are facing a future yet to be determined.
This time next year, an investigational drug hailed as a breakthrough in the science of cannabidiol could be prescribed to children suffering from treatment-resistant epilepsy.
The prospect of its success, however, has caused some unease in the American hemp industry.
London-based GW Pharmaceuticals is steering its proprietary Epidiolex oral solution through the U.S. Food and Drug Administration's approval pipeline.
Unlike other FDA-approved drugs that emulate the properties of THC, the psychoactive component of cannabis, Epidiolex utilizes another of the plant's compounds: non-psychoactive cannabidiol. GW's pharmaceutical formulation of purified CBD is targeted for treating rare, early onset seizure disorders including Dravet and Lennox-Gastaut syndromes, as well as Tuberous Sclerosis Complex and Infantile Spasms.